Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial

In this open-label phase II (n=321), 12 weeks of sofosbuvir 400 mg with velpatasvir 100mg, and with or without ribavirin resulted in high sustained virologic response rates (88-100%) in treatment-experienced patients with genotype 1-3 HCV infection.

The study involved genotype 1-3 HCV infection patients who either did not have cirrhosis or had compensated cirrhosis, as well as patients with genotype 1 HCV infection that was unsuccessfully treated with a protease inhibitor plus peginterferon or ribavirin.

 

Velpatasvir is a pan-genotypic NS5A inhibitor and sofosbuvir is a second-generation nucleotide analogue that inhibits the NS5B protein. This fixed dose combination clears HCV for the majority of people without need for interferon. It offers broad coverage of HCV genotypes. It is not currently licensed.